Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vanguard High Dividend Yield ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.92 (market cap $763.64M), while Vanguard High Dividend Yield ETF trades at $158.88 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 132× Ginkgo Bioworks Holdings Inc's market cap, and Vanguard High Dividend Yield ETF is more actively traded (908,176 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Vanguard High Dividend Yield ETF for 139 Days on average.
| DNA | VYM | |
|---|---|---|
Market Cap | $763.64M | $100.80B |
Volume | 3,204,177 | 908,176 |
Sector | Health | — |
52-Week High | $15.83 | $167.03 |
52-Week Low | $5.48 | $137.47 |
Typical Hold Time | 7 Days | 139 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
VYM trades at $158.76, up 0.83% with a bearish technical signal. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD. Support levels cluster near $156-157, while resistance sits at $159-160. Recent news questions VYM's stock selection methodology after dividend cuts in holdings like Intel and Walgreens.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include concentrated exposure to dividend-cut vulnerabilities and inflation persistence. Opportunities lie in Vanguard's low-cost, diversified approach for income-focused investors, though superior total return potential exists elsewhere.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
